Lilly buys AtaiBeckley·$3.8bn Otsuka buys Transcend·$1.2bn AbbVie buys Gilgamesh·$1.2bn atai buys Beckley Psytech·terms undisclosed AbbVie takes an option on Gilgamesh·$2bn Lilly buys AtaiBeckley·$3.8bn Otsuka buys Transcend·$1.2bn AbbVie buys Gilgamesh·$1.2bn atai buys Beckley Psytech·terms undisclosed AbbVie takes an option on Gilgamesh·$2bn Lilly buys AtaiBeckley·$3.8bn Otsuka buys Transcend·$1.2bn AbbVie buys Gilgamesh·$1.2bn atai buys Beckley Psytech·terms undisclosed AbbVie takes an option on Gilgamesh·$2bn

Next issueIssue 16 · Tue 29 Sep

Definium Therapeutics

Every issue covering Definium Therapeutics.

3 issues

2026-09-15No. 14
Five countries, one regulator.
2026-09-08No. 13
Three authorised, one counted.
2026-06-30No. 4
LSD just posted the biggest depression number in psychedelic Phase 3 history.